This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks.com featured highlights include: ConocoPhillips, Tyson Foods, Inc., AMN Healthcare Services, Inc., WESCO International, Inc. and Capri Holdings Ltd
by Zacks Equity Research
ConocoPhillips, Tyson Foods, Inc., AMN Healthcare Services, Inc., WESCO International, Inc. and Capri Holdings Ltd are highlighted in this Screen of the Week article.
Looking for a Growth Stock? 3 Reasons Why AMN Healthcare (AMN) is a Solid Choice
by Zacks Equity Research
AMN Healthcare (AMN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
OPKO Health's (OPK) Q4 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
OPKO Health's (OPK) fourth-quarter results benefit from continued strength in its Pharmaceuticals segment.
Merit Medical's (MMSI) Q4 Earnings, Revenues Top Estimates
by Zacks Equity Research
Merit Medical (MMSI), in the fourth quarter, benefits from revenue growth in both its segments, and from majority of the product categories within its Cardiovascular unit.
Here's Why You Should Invest In Henry Schein (HSIC) Now
by Zacks Equity Research
Investors are optimistic about Henry Schein's (HSIC) favorable dental business trends and bullish fourth-quarter 2021 performance.
Thermo Fisher (TMO) Extends Collaboration With Moderna
by Zacks Equity Research
Thermo Fisher (TMO) continues to be a trusted partner of Moderna, bringing a wide range of products and services enabling Moderna to deliver innovative medicines at an extraordinary speed and scale.
Use Relative Price Strength to Survive the Market Turmoil
by Nilanjan Choudhury
ConocoPhillips (COP), Tyson Foods (TSN), AMN Healthcare (AMN), WESCO International (WCC) and Capri Holdings (CPRI) are five stocks with explosive relative price strength.
Thermo Fisher (TMO) COVID Test Sales Grow, FX Woes Persist
by Zacks Equity Research
Thermo Fisher's (TMO) strong pandemic response stance enables it to accelerate its growth strategy, and bump up investments, which encourages it to raise the 2022 core organic growth guidance.
Allscripts' (MDRX) Q4 Earnings Beat Estimates, Margins Up
by Debanjana Dey
Allscripts' (MDRX) robust Q4 results demonstrate strength in both segments.
Nevro's (NVRO) Q4 Earnings in Line, Revenues Beat Estimates
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q4 due to soft geographical performances.
Earnings Estimates Rising for AMN Healthcare (AMN): Will It Gain?
by Zacks Equity Research
AMN Healthcare (AMN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Avanos Medical (AVNS) Q4 Earnings, Revenues Top Estimates
by Zacks Equity Research
Avanos Medical's (AVNS) fourth-quarter 2021 results gain from strength in the chronic care segment.
AMN Healthcare Services and The Gap have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
AMN Healthcare Services and The Gap have been highlighted as Zacks Bull and Bear of the Day.
Bull of the Day: AMN Healthcare (AMN)
by Tracey Ryniec
Healthcare solutions is red-hot in 2022.
Abbott (ABT) COVID Testing Sales Surge, FX Headwind Stays
by Zacks Equity Research
Abbott (ABT) registers strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.
New Strong Buy Stocks for February 23rd
by Zacks Equity Research
AMN, AN, BAK, CBOE, and TPH have been added to the Zacks Rank #1 (Strong Buy) List on February 23, 2022.
Should Value Investors Pick AMN Healthcare Services (AMN)?
by Zacks Equity Research
Let's see if AMN Healthcare Services (AMN) stock is a good choice for value-oriented investors right now from multiple angles.
Medtronic's (MDT) Cryoablation Catheters Get FDA Expanded Nod
by Zacks Equity Research
Medtronic's (MDT) Cardiac Cryoablation is the only ablation catheter approved to treat pediatric AVNRT.
NextGen (NXGN)-Verato Tie Up to Improve Patient Insights
by Zacks Equity Research
NextGen (NXGN) expects to deliver better insights into patient health history with its latest collaboration with Verato.
AMN Healthcare (AMN) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) robust Q4 results demonstrate its segmental strength.
AMN Healthcare Services (AMN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare (AMN) delivered earnings and revenue surprises of 14.34% and 0.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Veeva Systems (VEEV) Vault CDMS to Aid Idorsia's Clinical Trials
by Zacks Equity Research
Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Veeva Development Cloud business.
Phibro (PAHC) Up 17.1% Since Q2 Earnings: What's Driving It?
by Zacks Equity Research
Phibro's (PAHC) stock rallies on continued demand for its products globally and raised 2022 guidance.
AMN vs. GDRX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMN vs. GDRX: Which Stock Is the Better Value Option?